Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the ‘gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early breast cancer

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

First, to evaluate whether the benefits of combined chemotherapy (CT) and Tamoxifen (T), previously documented in the GROCTA-01 Trial, were long-lasting and, second, to show whether ER or PgR levels could allow the identification of the patients who could benefit from T alone. 504 node-positive, ER-positive, women were randomly assigned to ten CT courses or to 5 years of T or to the combination of the two (CTT). Disease-free (DFS) and overall survival (OS) were the primary trial-endpoints. DFS data were updated in 75% of the patients and S data in 95% of them. Cox regression models were used to check for prognostic features to estimate hazard ratios for treatment comparisons and to test for possible interaction between variables and treatment effects. Interactions between treatments and ER or PgR median levels were studied with the sub-population treatment effect pattern plot (STEPP) methodology. After a median follow-up time of 21 years, the DFS and OS benefits, previously favouring T over CT, continued to be observed, even though they were more evident in the first 6–7 years. The CTT advantages of DFS and OS over T alone were also confirmed. However, the additional benefit was limited to the first 10–12 years as S curves crossed over afterwards. After STEPP analysis, neither ER nor PgR concentrations fully discriminated the patients who could benefit from T alone. Even after such a long follow-up time, we have demonstrated that T is an effective alternative to CT for node-positive, ER-positive, breast cancer patients, regardless of their actual menopausal status, and that the additional benefit, especially on late survival, provided by the addition of CT to this anti-oestrogen, was minimal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. National Comprehensive Cancer Network (2010) NCCN practice guidelines in oncology. Invasive breast cancer v.3. www.nccn.org

  2. Thürlimann B, Price KN, Gelber RD et al (2009) Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11–93. Breast Cancer Res Treat 113:137–144

    Article  PubMed  Google Scholar 

  3. Pagani O, Gelber S, Simoncini E et al (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93. Breast Cancer Res Treat 116:491–500

    Article  PubMed  CAS  Google Scholar 

  4. Albain KS, Barlow WE, Ravdin PM et al (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055–2063

    Article  PubMed  Google Scholar 

  5. Fisher B, Redmond C, Legault-Poisson S et al (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16 tral. J Clin Oncol 8:1005–1018

    PubMed  CAS  Google Scholar 

  6. Boccardo F, Rubagotti A, Bruzzi P et al (1990) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. J Clin Oncol 8:1310–1320

    PubMed  CAS  Google Scholar 

  7. Rivkin SE, Green S, Metch B et al (1994) Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 12:2078–2085

    PubMed  CAS  Google Scholar 

  8. International Breast Cancer Study Group (1997) Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385–1394

    CAS  Google Scholar 

  9. Pritchard KI, Paterson AH, Fine S et al (1997) Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive, estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:2302–2311

    PubMed  CAS  Google Scholar 

  10. International Breast Cancer Study Group (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol 24:1332–1341

    Article  Google Scholar 

  11. Gelber RD, Cole BF, Goldhirsch A et al (1996) Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality adjusted survival. Lancet 347:1066–1071

    Article  PubMed  CAS  Google Scholar 

  12. Early Breast Cancer Trialist’s Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-years survival: an overview on the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  13. Boccardo F, Rubagotti A, Amoroso D et al (1992) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 28:673–680

    Article  PubMed  CAS  Google Scholar 

  14. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observation. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  15. Cox DR (1972) Regression model and life tables. J R Stat Soc B 34:187–220

    Google Scholar 

  16. Bonetti M, Gelber RD (2000) A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595–2609

    Article  PubMed  CAS  Google Scholar 

  17. Jones MC, Wand MP (1994) Kernel smoothing. CRC Press, Boca Raton

    Google Scholar 

  18. Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154

    Article  Google Scholar 

  19. Pritchard KI (2008) Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 112:718–722

    Article  PubMed  CAS  Google Scholar 

  20. Pico C, Martin M, Jara C et al (2004) Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 15:79–87

    Article  PubMed  CAS  Google Scholar 

  21. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329

    Article  PubMed  CAS  Google Scholar 

  22. Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261

    Article  PubMed  CAS  Google Scholar 

  23. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734

    Article  PubMed  CAS  Google Scholar 

  24. Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The GROCTA 01 trial was originally funded in part by an unrestricted grant from ICI-Pharma (Milan, Italy). No funding was obtained by any entity to support this analysis. The authors are indebted to M. Parodi and L. Zinoli (National Cancer Research Institute, Genoa, Italy) for their assistance in Data Management and to Dr C. Casella (Genoa Tumor Registry) for her valuable help in mortality data updating. They are also indebted to Ms. Suzanne Patten for reviewing the language format. Finally, they wish to express their gratitude to all the patients and the investigators who participated in this trial, namely, to the investigators listed below who have actively contributed to updating all data: M. Cantore (Ospedale Civile, Carrara); M. Mangoni (Ospedale Careggi, Firenze); C. Caroti (Ospedale Galliera, Genova); E. Rinaldi (Ospedale Civile, Magenta); E. Aitini (Ospedale Civile, Mantova); S. Banducci (Ospedale Civile, Merate); S. Girelli (Ospedale Fatebenefratelli, Milano); D. Aldigretti (Istituto Scientifico St Raffaele, Milano); B. Agostara, A. Traina (Ospedale Oncologico M. Ascoli, Palermo); G. Cruciani (Ospedale S. Maria delle Croci, Ravenna); C. Boni, R. Gnoni (Ospedale S. Maria Nuova, Reggio Emilia); D. Guarneri (Ospedale Civile, Sanremo); A. Farris, A. Lai (Oncologia Clinica, Università, Sassari); P.Sismondi, N.Biglia (I Clinica Ostetrica e Ginecologica, Università, Torino); M. Mansutti (Azienda Ospedaliera, Udine).

Author information

Authors and Affiliations

  1. Department of Oncology, Biology and Genetics, University of Genoa, Largo Rosanna Benzi 10, Genoa, Italy

    Francesco Boccardo, Pamela Guglielmini & Alessandra Rubagotti

  2. Department of Medical Oncology, National Cancer Research Institute, 16132, Genoa, Italy

    Francesco Boccardo, Pamela Guglielmini & Alessandra Rubagotti

  3. Department of Biostatistics, University “La Bicocca”, Milan, Italy

    Andrea Parodi

Authors
  1. Francesco Boccardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pamela Guglielmini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Parodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandra Rubagotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Boccardo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boccardo, F., Guglielmini, P., Parodi, A. et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the ‘gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early breast cancer. Breast Cancer Res Treat 126, 653–661 (2011). https://doi.org/10.1007/s10549-011-1405-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1405-6

Keywords

Search

Navigation